JAN 25, 2017 8:37 PM PST

Dendritic Cells Found Inside Growing Tumors

WRITTEN BY: Kara Marker

 

The immune system pulls out all the stops to try and prevent cancer cells from replicating and moving throughout the body, but tumors have their own methods of evasion. However, while in the past experts thought that cancer cells completely inhibited dendritic cells from activating the immune system, new findings show that dendritic cells are present after all.

Dendritic cells are the immune cells charged with initiating the immune response by processing antigens found in the bloodstream and making them visible to other immune cells. In a recent study from The Flanders Institute for Biotechnology (VIB), researchers found two dendritic cell types living within tumors: cDC1 and cDC2.

Both of these dendritic cells are connected to different immune responses, and they are both present in human and mouse tumors. In their discovery of these two immune cells in tumors, researchers were extremely surprised.

However surprising the finding, researchers from the VIB are now focused on a type of cancer “vaccination” using cDC1 and cDC2 to inhibit current cancer growth and prevent future growth. Their new approach is to take dendritic cells from surgically-removed tumors for “vaccination.”

"We believe that DCs taken from tumors are well-suited for cancer immunotherapy, since they've been confirmed present within removed tumors and cause a strong anti-tumor response even in low numbers,” explained professor Van Ginderachter.

The connection between dendritic cells and cancer immunotherapy has been heavily researched, and now Ginderachter has his sights set out understanding why some tumors respond to cDC2 better than cDC1 and vice versa.

“Logically, the next step will be to find out whether vaccination will be successful in a therapeutic setting,” Ginderachter said. “We will have to remove the tumor, isolate the dendritic cells and then re-inject them into the same individual to discover whether we can prevent the formation of new tumors and relapse of the main tumor.”

The study was recently published in the journal Nature Communications.

Sources: VIB, The Rockefeller University

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 10, 2020
Immunology
FEB 10, 2020
Measles infections can give the immune system amnesia
The immune system detects the presence of invading microbes that it recognizes from previous infections, and initiates a ...
MAR 03, 2020
Clinical & Molecular DX
MAR 03, 2020
Singapore charges ahead with antibody-based test for COVID-19
Researchers, biotech and pharmaceutical companies are scrambling to put an end to the coronavirus disease (COVID-19) out ...
MAR 19, 2020
Infographics
MAR 19, 2020
All You Need to Know About Coronavirus (CoVID-19)
A new coronavirus, first identified in China in December 2019, has caused an outbreak of respiratory illness that was re ...
APR 07, 2020
Microbiology
APR 07, 2020
Second COVID-19 Vaccine Enters Human Trials
Yesterday, Inovio Pharmaceuticals, Inc. announced that it will begin human trials on a potential vaccine for COVID-19.
APR 20, 2020
Cell & Molecular Biology
APR 20, 2020
Worst COVID-19 Cases May be Caused by Immune Cell Overactivity
The SARS-CoV-2 virus causea huge range of symptoms, and researchers are learning more about the worst cases, which may h ...
MAY 06, 2020
Drug Discovery & Development
MAY 06, 2020
Breakthrough in Antibody Treatment for COVID-19
Israeli scientists have announced significant progress in isolating an antibody that may be effective in treating those ...
Loading Comments...